Atezolizumab (Tecentriq, Roche) is indicated for 'adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD‑L1 expression on ≥ 50% of tumour cells and who do not have EGFR‑mutant or ALK‑positive NSCLC'.
The dosage schedule is available in the summary of product characteristics for atezolizumab.
The list price for atezolizumab is £2,665.38 for an 840‑mg vial or £3,807.69 for a 1,200‑mg vial (excluding VAT, BNF online, accessed March 2025).
The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Roche's website on sustainability.